Mylan settles cancer drug patent dispute with Genentech
15-03-2017
warchi / iStockphoto.com
Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
oncology, cancer, cancer therapy, Chugai Pharmaceuticals, Nippon Kayaku, Roche, Genentech, Tokyo District Court
